2 Healthcare Dividend Stocks That Are Screaming Buys in November

In the ever-evolving investment landscape, dividend stocks remain a reliable and attractive option for income-focused investors. The healthcare sector, in particular, offers compelling opportunities with its stable growth and high dividend yields. This article highlights two healthcare dividend stocks that stand out as screaming buys in November: Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ).



1. Royalty Pharma plc (RPRX)

Royalty Pharma is a biopharmaceutical company that specializes in acquiring royalty interests in approved or late-stage biopharmaceutical products. With a 3.05% dividend yield and a strong balance sheet, RPRX is an attractive option for income-focused investors.

RPRX's recent $350 million royalty funding agreement with Syndax Pharmaceuticals for Niktimvo is a key catalyst for growth. This strategic partnership, along with RPRX's robust pipeline and strong cash flow generation, positions the company well for future acquisitions and investments.



2. Johnson & Johnson (JNJ)

Johnson & Johnson, a multinational corporation, is a well-known name in the healthcare industry. With a diverse portfolio of pharmaceuticals, medical devices, and consumer health products, JNJ offers a 3.13% dividend yield and a 59-year history of dividend increases.

JNJ's recent positive Phase 3 GRAVITI study results for Tremfya in Crohn's disease further strengthen its pipeline. The company's strong brand, global presence, and consistent dividend growth make it an attractive long-term investment.



Both RPRX and JNJ are well-positioned to capitalize on the growing demand for healthcare services and products, driven by an aging population and increasing healthcare spending. Their strong fundamentals, robust pipelines, and high dividend yields make them compelling investment opportunities in November.

In conclusion, Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ) are two healthcare dividend stocks that offer attractive yields, strong fundamentals, and growth potential. As income-focused investors, we should consider these stocks as screaming buys in November, given their stable dividends, undervalued valuations, and promising pipelines. By investing in these healthcare dividend stocks, we can secure consistent, inflation-protected income and capitalize on the long-term growth prospects of the healthcare sector.